Adipose Tissue and Inflammation in Coronary Heart Disease
NCT ID: NCT02760914
Last Updated: 2021-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
50 participants
OBSERVATIONAL
2016-06-30
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adipose Tissue Inflammation in HFpEF
NCT04886713
Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting
NCT01366469
Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery
NCT02488876
Assessment of Functional Capacity and Inflammatory Markers in Women With Heart Failure With Preserved Ejection Fraction
NCT02649400
INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery
NCT01020409
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be conducted according to the Declaration of Helsinki, and in accordance with approval from the Regional Ethics Committee.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coronary heart disease
Patients with coronary heart disease undergoing planned coronary artery bypass surgery
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Svein Solheim
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ingebjørg Seljeflot, Professor
Role: PRINCIPAL_INVESTIGATOR
Oslo University Hospital, Ullevål, Oslo, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Svein Solheim
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Opstad TB, Papotti B, Akra S, Hansen CH, Braathen B, Tonnessen T, Solheim S, Seljeflot I. Sirtuin1, not NAMPT, possesses anti-inflammatory effects in epicardial, pericardial and subcutaneous adipose tissue in patients with CHD. J Transl Med. 2023 Sep 21;21(1):644. doi: 10.1186/s12967-023-04518-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/441
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.